BMS-695735, a benzimidazole inhibitor of insulin-likegrowthfactor-1 receptor, has broad-spectrum antitumor activity in vivo. It was found that BMS-695735 had strong inhibition of CYP3A4, induction of CYP3A4 mediated by PXR transactivation, poor water so
ALK-IN-12 is a highly potent and orally active inhibitor of anaplastic lymphoma kinase (ALK), demonstrating an exceptional IC50 value of 0.18 nM. Additionally, ALK-IN-12 displays inhibitory activity against insulin-likegrowthfactor 1 receptor (IGF1R) and insulin receptor (InsR), with IC50 values of 20.3 nM and 90.6 nM, respectively. Notably, its antitumor effects have been observed, making it a promising compound for targeted cancer therapy.
IGF-1R inhibitor-2 (example 121) is a compound that inhibits the insulin-likegrowthfactor-1 receptor (IGF-1R). By downregulating the IGF-1R, it has the potential to reverse the transformed phenotype of tumor cells and make them more susceptible to apoptosis.
NBI-31772 hydrate is a powerful inhibitor of the interaction between insulin-likegrowthfactor (IGF) and IGF-binding proteins (IGFBPs). It acts as a nonpeptide ligand, effectively releasing bioactive IGF-I from the IGF-I IGFBP-3 complex (Ki values for all six human subtypes range from 1-24 nM). This compound demonstrates significant anxiolytic and antidepressant-like effects [1] [2] [3].